

Risk Groups Recommended for PPSV23	PPSV23 Schedule
(Pneumococcal Polysaccharide Vaccine)	115 V 25 Schedule
Vaccinate persons aged 2-64 years:	Persons who are Immunocompetent should receive:
 With chronic cardiovascular disease (including cong 	
failure, cardiomyopathies), chronic pulmonary disease	
COPD and emphysema) or diabetes mellitus	1 dose of 115 v25 avaiter age 05 years
With alcoholism or chronic liver disease (including cirr	chosis) Use a minimum of 5 years between PPSV23 doses
Within environments or settings with identified increas	
Who have a cerebrospinal fluid (CSF) leak	PCV13 is also indicated for persons with CSF leaks and cochlear
Who have a cochlear implant	implants (see below)
Vaccinate persons aged 2-64 years:	Persons with asplenia or who are immunocompromised should
With functional or anatomic asplenia (including sickle	cell disease receive:
and splenectomy)	• 2 doses of PPSV23 between the ages of 2-64 years
• With immunocompromising conditions including HIV	
leukemia, lymphoma, Hodgkin's disease, multiple mye	
generalized malignancy, chronic renal failure or nephro	
 syndromes, congenital or acquired immunodeficiencies Who have diseases with treatment using immunosuppre 	
Who have diseases with treatment using immunosuppredrugs, including long-term systemic corticosteroids or including long-term systemic corticosteroids.	
therapy	(See Delow)
Who have received solid organ transplantation	
Vaccinate persons aged 19-64 years:	Persons with one or more of these risk factors should receive:
With asthma or who smoke cigarettes	• 1 dose of PPSV23 between the ages of 2-64 years
	1 dose of PPSV23 at/after age 65 years
	Use a minimum interval of 5 years between PPSV23 doses
Risk Groups Recommended for PCV13	PCV13 Schedule
(Pneumococcal Conjugate Vaccine)	
Vaccinate persons aged 19-64 years:	For all persons who are 19-64 years:
Who have a CSF leak or cochlear implant	• 1 dose of PCV13 ¹
• With functional or anatomic asplenia (including sickle	cell disease
and splenectomy)	Preferred that PCV13 be given before any doses of PPSV23
With immunocompromising conditions including HIV	
leukemia, lymphoma, Hodgkin's disease, multiple mye	
generalized malignancy, chronic renal failure or nephro	
syndromes, congenital or acquired immunodeficiencies	
Who have diseases with treatment using immunosuppredrugs, including long-term systemic corticosteroids or a second contraction.	
therapy	doses
Who have received solid organ transplantation	
Routine Pneumococcal Vaccination for Persons A	aged 65 PCV13 and PPSV23 Schedule
Years and Older	10 115 and 115 125 benedule
Vaccinate persons aged 65 years or older:	For persons 65 years or older who need PCV13 and PPSV23 ² :
• Who have never received 1 dose of PCV13 ¹	Administer PCV13 first (preferred)
- THO HAVE HEVEL LECELY COLL GUSC OF LC V 15	- Administer I C v 13 mist (preferred)
Who have not received 1 dose of PPSV23 at/after age 6.	55 years • Administer PPSV23 6-12 months later
Who have not received 1 dose of PPSV23 at/after age 6	
• Who have not received 1 dose of PPSV23 at/after age 6 If there is no previous history of PCV13 and/or PPSV23 vac	• Minimum interval between PCV13 given 1 st & PPSV23 is 8
	• Minimum interval between PCV13 given 1 st & PPSV23 is 8 weeks
If there is no previous history of PCV13 and/or PPSV23 vac	• Minimum interval between PCV13 given 1 st & PPSV23 is 8 weeks
If there is no previous history of PCV13 and/or PPSV23 vac	 Minimum interval between PCV13 given 1st & PPSV23 is 8 weeks If PPSV23 was administered 1st, the minimum interval prior to
If there is no previous history of PCV13 and/or PPSV23 vac	 Minimum interval between PCV13 given 1st & PPSV23 is 8 weeks If PPSV23 was administered 1st, the minimum interval prior to administering PCV13 is at least one year

¹If a previous dose of PCV13 has been administered, an additional dose is not recommended.

²If both vaccines are recommended, administer at separate visits. PCV13 first (preferred) then PPSV23, ensuring minimum intervals are met.

Resources: Use of PCV13 & PPSV23 in Adults with Immunocompromising Conditions, ACIP Recommendations, MMWR 61 (40) October 12, 2012; Updated Recommendations for Prevention of Invasive Pneumococcal Disease in Adults using PPSV23, MMWR 59(24) September 10, 2010; Use of PCv13 and PPSV23 Among Adults aged 65 Years, Recommendations of ACIP, MMWR 63(37) September 19, 2014. Available at www.cdc.gov/vaccines